Paul Emery Selected Research

Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

1/2023	DNA Hypomethylation in the TNF-Alpha Gene Predicts Rheumatoid Arthritis Classification in Patients with Early Inflammatory Symptoms.
12/2016	A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
3/2016	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.
12/2012	Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
10/2012	IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
4/2012	Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide.
11/2009	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
8/2009	Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
11/2008	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
10/2008	Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Emery Research Topics

Disease

276	Rheumatoid Arthritis 02/2024 - 02/2002
45	Synovitis 02/2024 - 03/2002
43	Arthritis (Polyarthritis) 04/2024 - 08/2002
40	Inflammation (Inflammations) 02/2024 - 02/2002
36	Necrosis 11/2020 - 01/2004
23	Infections 02/2023 - 06/2004
22	Pain (Aches) 02/2024 - 03/2007
19	Ankylosing Spondylitis 11/2021 - 01/2003
19	Rheumatic Diseases (Rheumatism) 01/2019 - 12/2003
18	Psoriatic Arthritis 06/2022 - 02/2003
17	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023 - 01/2004
16	Autoimmune Diseases (Autoimmune Disease) 02/2023 - 01/2004
11	Fatigue 09/2019 - 09/2006
8	Arthralgia (Joint Pain) 02/2024 - 10/2006
7	Edema (Dropsy) 01/2022 - 02/2002
7	Osteitis 01/2021 - 11/2011
6	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2023 - 05/2009
6	Fibrosis (Cirrhosis) 12/2021 - 11/2013
6	Neoplasms (Cancer) 03/2020 - 01/2005
6	Chronic Disease (Chronic Diseases) 09/2019 - 02/2002
6	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2019 - 06/2007
6	Systemic Scleroderma (Systemic Sclerosis) 01/2019 - 11/2002
6	Disease Progression 01/2018 - 01/2003
5	Skin Diseases (Skin Disease) 01/2020 - 05/2008
5	Osteoarthritis 07/2013 - 08/2002
4	COVID-19 02/2023 - 07/2020
4	Body Weight (Weight, Body) 12/2015 - 11/2003
3	Melanoma (Melanoma, Malignant) 12/2022 - 08/2016
3	Tenosynovitis 11/2021 - 10/2007
3	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2021 - 08/2013
3	Neutropenia 11/2019 - 12/2015
3	Periodontal Diseases (Periodontal Disease) 01/2019 - 09/2015
3	Hypertension (High Blood Pressure) 01/2018 - 03/2007
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2017 - 11/2002
3	Joint Diseases (Joint Disease) 02/2014 - 01/2008

Drug/Important Bio-Agent (IBA)

85	Methotrexate (Mexate)FDA LinkGeneric 09/2023 - 02/2002
55	Antirheumatic Agents (DMARD)IBA 02/2024 - 11/2003
53	Rituximab (Mabthera)FDA Link 12/2023 - 06/2004
35	Abatacept (Orencia)FDA Link 02/2024 - 06/2002
34	Etanercept (Enbrel)FDA Link 09/2023 - 01/2004
31	Biomarkers (Surrogate Marker)IBA 02/2024 - 11/2003
29	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023 - 07/2002
25	AutoantibodiesIBA 01/2023 - 10/2003
25	Infliximab (Remicade)FDA Link 01/2020 - 01/2004
24	Tumor Necrosis Factor InhibitorsIBA 11/2021 - 01/2003
23	Adalimumab (Humira)FDA Link 01/2020 - 01/2003
18	Anti-Citrullinated Protein AntibodiesIBA 04/2024 - 09/2010
16	golimumab FDA Link 01/2020 - 08/2009
15	tocilizumab (atlizumab)FDA Link 11/2020 - 12/2007
14	AntibodiesIBA 04/2024 - 12/2015
14	CytokinesIBA 03/2021 - 03/2004
14	Monoclonal AntibodiesIBA 01/2019 - 11/2004
13	Proteins (Proteins, Gene)FDA Link 02/2024 - 02/2003
13	Rheumatoid FactorIBA 02/2024 - 11/2003
13	baricitinibIBA 01/2021 - 01/2017
13	C-Reactive ProteinIBA 01/2019 - 11/2003
12	Interleukin-6 (Interleukin 6)IBA 01/2023 - 02/2012
12	Biosimilar PharmaceuticalsIBA 06/2022 - 03/2014
12	Certolizumab Pegol FDA Link 01/2020 - 11/2008
11	GlucocorticoidsIBA 11/2023 - 05/2006
11	ametantrone (HAQ)IBA 01/2022 - 09/2006
11	Leflunomide (Arava)FDA LinkGeneric 01/2020 - 02/2002
10	Peptides (Polypeptides)IBA 04/2024 - 10/2012
8	cyclic citrullinated peptideIBA 02/2024 - 09/2009
8	secukinumabIBA 01/2019 - 11/2013
7	Immunoglobulin G (IgG)IBA 02/2023 - 12/2007
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2016 - 03/2002
7	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2014 - 08/2002
6	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2024 - 12/2006
6	Janus Kinase InhibitorsIBA 11/2023 - 06/2017
6	Interleukin-7 (Interleukin 7)IBA 12/2022 - 01/2005
5	Janus KinasesIBA 12/2023 - 06/2017
5	InterferonsIBA 01/2023 - 01/2016
5	EpitopesIBA 01/2022 - 05/2008
5	Methylprednisolone FDA LinkGeneric 11/2021 - 11/2002
5	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 06/2004
5	amsonic acid (DAS)IBA 03/2019 - 12/2003
5	Interleukin-17 (Interleukin 17)IBA 01/2018 - 11/2013
5	HLA-B27 Antigen (HLA B27 Antigen)IBA 09/2013 - 02/2002
5	GadoliniumIBA 08/2009 - 02/2002
4	Prednisolone (Predate)FDA LinkGeneric 02/2023 - 12/2006
4	sarilumabIBA 11/2020 - 06/2017
4	EnzymesIBA 07/2020 - 06/2004
4	Immunoglobulins (Immunoglobulin)IBA 08/2015 - 12/2007
4	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 04/2013 - 12/2007
3	AntigensIBA 02/2024 - 11/2003
3	VaccinesIBA 02/2023 - 01/2017
3	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2021 - 09/2015
3	Interferon Type IIBA 12/2020 - 10/2017
3	upadacitinibIBA 01/2020 - 12/2016
3	AutoantigensIBA 11/2017 - 07/2013
3	HLA-DRB1 Chains (HLA DRB1)IBA 01/2010 - 05/2008

Therapy/Procedure

107	Therapeutics 02/2024 - 02/2002
10	Biological Therapy 01/2023 - 01/2007
7	Aftercare (After-Treatment) 01/2019 - 02/2007
4	Drug Therapy (Chemotherapy) 07/2012 - 01/2004
3	Retreatment 01/2021 - 12/2011
3	Drug Tapering 01/2020 - 01/2018
3	Remission Induction 08/2013 - 01/2005
3	Injections 01/2011 - 01/2004